Print Page  Close Window

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
05/22/17Enumeral Reports First Quarter Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2017-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced its financial results for the three months ended March 31, 2017. Recent Business Highlights In May 2017, Enumeral received an aggregate of $668,000 in g... 
Printer Friendly Version
04/05/17Enumeral and ICAV to Pursue Infectious Disease Collaboration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 5, 2017-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced that Enumeral and the International Consortium on Anti-Virals (“ICAV”) have entered into a memorandum of understanding to pursue an infectious disease collaboration utilizing Enumeral's... 
Printer Friendly Version
03/28/17Enumeral Reports Year End 2016 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2017-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced its financial results for the year ended December 31, 2016. “Over the last several months we have been actively engaged in our turnaround plans for Enumeral,” said Wael ... 
Printer Friendly Version